Northwestern Mutual Wealth Management Co. grew its holdings in Doximity, Inc. (NYSE:DOCS – Free Report) by 325,436.6% in the 4th quarter, Holdings Channel reports. The fund owned 1,298,891 shares of the company’s stock after purchasing an additional 1,298,492 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Doximity were worth $57,515,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of DOCS. Royal Bank of Canada boosted its position in shares of Doximity by 24.2% during the first quarter. Royal Bank of Canada now owns 106,845 shares of the company’s stock worth $6,200,000 after buying an additional 20,847 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Doximity by 0.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,978 shares of the company’s stock worth $2,262,000 after buying an additional 210 shares during the period. NewEdge Advisors LLC boosted its position in shares of Doximity by 613.7% during the first quarter. NewEdge Advisors LLC now owns 6,323 shares of the company’s stock worth $367,000 after buying an additional 5,437 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Doximity by 33.3% during the first quarter. Goldman Sachs Group Inc. now owns 255,529 shares of the company’s stock worth $14,828,000 after buying an additional 63,873 shares during the period. Finally, Focus Partners Wealth acquired a new position in shares of Doximity during the first quarter worth about $283,000. 87.19% of the stock is currently owned by institutional investors.
Key Doximity News
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
- Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
- Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
- Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
- Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
- Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares
Insider Buying and Selling
Doximity Stock Performance
Shares of NYSE DOCS opened at $18.93 on Monday. The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of 19.12, a P/E/G ratio of 1.36 and a beta of 1.36. Doximity, Inc. has a 1-year low of $17.15 and a 1-year high of $76.51. The business’s 50 day moving average price is $23.94.
Doximity declared that its board has approved a share buyback program on Thursday, February 5th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price objective on Doximity from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Thursday. Weiss Ratings cut Doximity from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Jefferies Financial Group cut Doximity from a “buy” rating to a “hold” rating and reduced their price target for the company from $51.00 to $19.00 in a research report on Thursday. BTIG Research cut Doximity from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, BMO Capital Markets reduced their price target on Doximity from $25.00 to $20.00 and set a “market perform” rating for the company in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.62.
Check Out Our Latest Analysis on DOCS
Doximity Profile
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
See Also
- Five stocks we like better than Doximity
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NYSE:DOCS – Free Report).
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
